- Erratum
- Open access
- Published:
Erratum to: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus
BMC Infectious Diseases volume 4, Article number: 14 (2004)
The Original Article was published on 13 January 2004
Text
In our recent article [1], we did not declare the patent rights related to stampidine technology. Since they may potentially be viewed as non-financial competing interests despite the fact our employer is a non-profit public charity, we are now providing the following supplemental information:
FMU, AOV and HET are employees of Parker Hughes Institute, which has applied for a patent for the use of stampidine in the treatment of haemorrhagic fever. Parker Hughes Institute currently holds patents for the use of stampidine in other clinical conditions, with FMU listed as an inventor.
References
Uckun FU, Petkevich AS, Vassilev AO, Tibbles HE, Titov LP: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis. 2004, 4: 1-10.1186/1471-2334-4-1.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/4/14/prepub
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at 10.1186/1471-2334-4-1
Rights and permissions
About this article
Cite this article
Uckun, F.M., Petkevich, A.S., Vassilev, A.O. et al. Erratum to: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis 4, 14 (2004). https://doi.org/10.1186/1471-2334-4-14
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/1471-2334-4-14
Comments
View archived comments (1)